Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients

Rafael E Campo, C. Cohen, K. Grimm, T. Shangguan, J. Maa, D. Seekins

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Regimen selection in antiretroviral therapy can impact treatment adherence, quality of life (QoL) and treatment satisfaction, and may influence clinical outcome. We evaluated the effect of regimen switching on virological, safety and patientreported outcomes. In this 48-week, open-label, randomized, non-inferiority study, 262 HIV-1-infected adult patients with a viral load <50 copies/mL on protease inhibitor (PI)-based regimens were switched to either once-daily efavirenz, lamivudine and entericcoated didanosine (efavirenz-A [QD]) or once-daily efavirenz plus continuation of current nucleoside reverse transcriptase inhibitors (efavirenz-B). In the primary outcome of patients who maintained virological suppression at week 48, efavirenz-A (QD) was non-inferior to efavirenz-B (81% versus 79%, respectively). Both regimens were associated with low virological failure rates and significant improvements in treatment satisfaction, adherence and QoL after switching from PI-based therapy, with no differences between regimens. Switching from a PI- to an efavirenz-based regimen was generally safe and well tolerated.

Original languageEnglish
Pages (from-to)166-171
Number of pages6
JournalInternational Journal of STD and AIDS
Volume21
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

efavirenz
Protease Inhibitors
Quality of Life
Therapeutics
Didanosine
Reverse Transcriptase Inhibitors
Lamivudine
Viral Load
Nucleosides
HIV-1

Keywords

  • Adherence
  • Efavirenz
  • HIV
  • Once-daily dosing
  • Quality of life
  • Regimen switch
  • Treatment satisfaction

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients. / Campo, Rafael E; Cohen, C.; Grimm, K.; Shangguan, T.; Maa, J.; Seekins, D.

In: International Journal of STD and AIDS, Vol. 21, No. 3, 01.03.2010, p. 166-171.

Research output: Contribution to journalArticle

@article{d28772ee36004a1cb4701b7b49f643a2,
title = "Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients",
abstract = "Regimen selection in antiretroviral therapy can impact treatment adherence, quality of life (QoL) and treatment satisfaction, and may influence clinical outcome. We evaluated the effect of regimen switching on virological, safety and patientreported outcomes. In this 48-week, open-label, randomized, non-inferiority study, 262 HIV-1-infected adult patients with a viral load <50 copies/mL on protease inhibitor (PI)-based regimens were switched to either once-daily efavirenz, lamivudine and entericcoated didanosine (efavirenz-A [QD]) or once-daily efavirenz plus continuation of current nucleoside reverse transcriptase inhibitors (efavirenz-B). In the primary outcome of patients who maintained virological suppression at week 48, efavirenz-A (QD) was non-inferior to efavirenz-B (81{\%} versus 79{\%}, respectively). Both regimens were associated with low virological failure rates and significant improvements in treatment satisfaction, adherence and QoL after switching from PI-based therapy, with no differences between regimens. Switching from a PI- to an efavirenz-based regimen was generally safe and well tolerated.",
keywords = "Adherence, Efavirenz, HIV, Once-daily dosing, Quality of life, Regimen switch, Treatment satisfaction",
author = "Campo, {Rafael E} and C. Cohen and K. Grimm and T. Shangguan and J. Maa and D. Seekins",
year = "2010",
month = "3",
day = "1",
doi = "10.1258/ijsa.2009.008487",
language = "English",
volume = "21",
pages = "166--171",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients

AU - Campo, Rafael E

AU - Cohen, C.

AU - Grimm, K.

AU - Shangguan, T.

AU - Maa, J.

AU - Seekins, D.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Regimen selection in antiretroviral therapy can impact treatment adherence, quality of life (QoL) and treatment satisfaction, and may influence clinical outcome. We evaluated the effect of regimen switching on virological, safety and patientreported outcomes. In this 48-week, open-label, randomized, non-inferiority study, 262 HIV-1-infected adult patients with a viral load <50 copies/mL on protease inhibitor (PI)-based regimens were switched to either once-daily efavirenz, lamivudine and entericcoated didanosine (efavirenz-A [QD]) or once-daily efavirenz plus continuation of current nucleoside reverse transcriptase inhibitors (efavirenz-B). In the primary outcome of patients who maintained virological suppression at week 48, efavirenz-A (QD) was non-inferior to efavirenz-B (81% versus 79%, respectively). Both regimens were associated with low virological failure rates and significant improvements in treatment satisfaction, adherence and QoL after switching from PI-based therapy, with no differences between regimens. Switching from a PI- to an efavirenz-based regimen was generally safe and well tolerated.

AB - Regimen selection in antiretroviral therapy can impact treatment adherence, quality of life (QoL) and treatment satisfaction, and may influence clinical outcome. We evaluated the effect of regimen switching on virological, safety and patientreported outcomes. In this 48-week, open-label, randomized, non-inferiority study, 262 HIV-1-infected adult patients with a viral load <50 copies/mL on protease inhibitor (PI)-based regimens were switched to either once-daily efavirenz, lamivudine and entericcoated didanosine (efavirenz-A [QD]) or once-daily efavirenz plus continuation of current nucleoside reverse transcriptase inhibitors (efavirenz-B). In the primary outcome of patients who maintained virological suppression at week 48, efavirenz-A (QD) was non-inferior to efavirenz-B (81% versus 79%, respectively). Both regimens were associated with low virological failure rates and significant improvements in treatment satisfaction, adherence and QoL after switching from PI-based therapy, with no differences between regimens. Switching from a PI- to an efavirenz-based regimen was generally safe and well tolerated.

KW - Adherence

KW - Efavirenz

KW - HIV

KW - Once-daily dosing

KW - Quality of life

KW - Regimen switch

KW - Treatment satisfaction

UR - http://www.scopus.com/inward/record.url?scp=77949364237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949364237&partnerID=8YFLogxK

U2 - 10.1258/ijsa.2009.008487

DO - 10.1258/ijsa.2009.008487

M3 - Article

C2 - 20215619

AN - SCOPUS:77949364237

VL - 21

SP - 166

EP - 171

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 3

ER -